HLA-B*5701 frequency in Chilean HIV-infected patients and in general population
Braz. j. infect. dis
;
14(5): 510-512, Sept.-Oct. 2010. ilus, tab
Article
in English
| LILACS
| ID: lil-570568
ABSTRACT
It has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to determine the carrier frequency prior to its use for the screening of HIV-infected patients.The aim of this study was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients referred for B*5701 typing. For that purpose 300 blood bank donors and 492 abacavir-naïve HIV-infected patients from Chile were screened for B*5701 by a sequence specific primer PCR.We detected 14/300 (4.7 percent) B*57-positive individuals in the Chilean general population, 11 (3.7 percent) were B*5701 positive, and 3 (1 percent) had another subtype.All were heterozygous,thus a B*5701 allele frequency of 2 percent was determined.Eleven of 492 (2.2 percent) HIV-patients carried a B*5701 allele. The difference between these frequencies is probably due to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral therapy and B*5701 typing. Considering the usefulness of B*5701 screening, its prevalence in the Chilean general population,and the availability of a validated method,we conclude that HLA-B*5701 typing in Chilean HIV-infected patients about to initiate abacavir treatment is strongly recommended.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Dideoxynucleosides
/
HLA-B Antigens
/
HIV Infections
/
Anti-HIV Agents
/
Drug Hypersensitivity
Type of study:
Observational study
/
Prevalence study
/
Risk factors
Limits:
Humans
Country/Region as subject:
South America
/
Chile
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS